Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Xetra  >  Merck KGaA    MRK   DE0006599905

MERCK KGAA (MRK)
Mes dernières consult.
Most popular
Report
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Xetra
10/16/2017 10/17/2017 10/18/2017 10/19/2017 10/20/2017 Date
96.9(c) 94.64(c) 94.51(c) 94.5(c) 93.93(c) Last
237 260 846 074 450 590 551 672 506 410 Volume
+0.58% -2.33% -0.14% -0.01% -0.60% Change
More quotes
Financials (€)
Sales 2017 15 390 M
EBIT 2017 3 450 M
Net income 2017 1 737 M
Debt 2017 9 928 M
Yield 2017 1,35%
Sales 2018 15 662 M
EBIT 2018 3 390 M
Net income 2018 1 892 M
Debt 2018 7 925 M
Yield 2018 1,43%
P/E ratio 2017 21,86
P/E ratio 2018 20,05
EV / Sales2017 1,43x
EV / Sales2018 1,28x
Capitalization 12 140 M
More Financials
Company
Merck KGaA engages in the manufacturing of pharmaceutical and chemical products.It operates through the following segments: Healthcare, Life Science, and Performance Materials.The Healthcare segment comprises the businesses with prescription and over-the-counter pharmaceuticals and... 
Sector
Pharmaceuticals
Calendar
11/09Earnings Release
More about the company
Surperformance© ratings of Merck KGaA
Trading Rating : Investor Rating :
More Ratings
Latest news on MERCK KGAA
10/20 MERCK : Brings Customers Closer to Gene Therapy Product Commercialization
10/20 MERCK KGAA : Release according to Article 26, Section 1 of the WpHG [the German ..
10/20 MERCK : Darmstadt, Germany, Named a Top Employer by Science Magazine
10/20 MERCK : Darmstadt, Germany, receives award for its “Advanced Light Protect..
10/20 PURSUING NOVEL PATHWAYS IN IMMUNOLOG : Merck KGaA, Darmstadt, Germany Presents N..
10/19 MERCK : Darmstadt, Germany, Brings Customers Closer to Gene Therapy Product Comm..
10/13 MERCK : MilliporeSigma Opens New Life Science Center in Massachusetts for Scient..
10/12 MERCK : The Millipore Curiosity Cube
10/12 MERCK : Learning in the Cube
10/12 MERCK KGAA : gives back to society through Merck Foundation’s program to i..
More news
Sector news : Specialty & Advanced Pharmaceuticals
10/20DJMERCK AND : to Lay Off About 1,800 U.S. Sales Reps in Cost-Cutting Move
10/20 MERCK AND : to cut 1,800 U.S. sales jobs, add 960 in chronic care
10/20DJABBOTT LABORATORIES : Hacking Is a Risk for Pacemakers. So Is the Fix
10/19DJCELGENE : Halts Crohn's Disease Drug Trials
10/19DJEuropean Corporate Roundup for Thursday
More sector news : Specialty & Advanced Pharmaceuticals
4-Traders Strategies on MERCK KGAA 
MERCK KGAA - 07/25
The downward trend should continue
SELL
MERCK KGAA - 2016
Towards the breakout of a major resistance level
BUY
More Strategies
Latest Tweets
09:20aMerck to cut 1,800 U.S. sales jobs, add 960 in chronic care
6
06:21aMerck to fire around 7% of its US staff  
03:15aMerck plans to lay off about 1,800 U.S. sales representatives
62
02:30aMerck to cut 1,800 U.S. sales jobs, add 960 in chronic care
5
01:33aMerck to lay off about 1,800 U.S. sales reps in cost-cutting move
1
More tweets
Qtime:261
News from SeekingAlpha
10/13 Merck KGaA's Bavencio an Orphan Drug for gastric cancer
09/28 Merck KGaA (MKGAY) Investor Presentation - Slideshow
09/28 YOUR DAILY PHARMA SCOOP : Celgene's CELMoD Potential, Allergan's Senate Troubles..
09/27 Pfizer and Merck KGaA's Bavencio OK'd in Japan for rare skin cancer
09/24 WEEK IN REVIEW : Zai Lab Completes $150 Million U.S. IPO; Investors Push Valuati..
Chart MERCK KGAA
Duration : Period :
Merck KGaA Technical Analysis Chart | MRK | DE0006599905 | 4-Traders
Technical analysis trends MERCK KGAA
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 110 €
Spread / Average Target 17%
EPS Revisions
Managers
NameTitle
Wolfgang Heinz Büchele Chairman-Supervisory Board
Marcus Kuhnert Chief Financial Officer
Crocifissa Attardo Member-Supervisory Board
Mechthild Auge Member-Supervisory Board
Michael Fletterich Vice Chairman-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
MERCK KGAA-4.68%14 304
ABBVIE53.37%153 097
KYOWA HAKKO KIRIN CO LTD24.97%10 167
JAZZ PHARMACEUTICALS PLC28.83%8 437
ZHANGZHOU PIENTZEHUANG PHARMACEUTICL LTD33.70%5 792
CONVATEC GROUP-9.02%5 572